Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 14/20 | 0.54 |
| ▸ | HTR1B | P28222 | 12/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7480727 | 0.84 | HTR1D (0.70) | HTR1DHTR1BHTR2C | |
| SCHEMBL6945185 | 0.82 | HTR1D (0.64) | HTR1DHTR1BHTR2CCYP2D6HTR1A | |
| SCHEMBL7480332 | 0.78 | HTR2C (0.73) | HTR1DHTR1BHTR2CCYP2D6TBXAS1 | |
| SCHEMBL8663664 | 0.77 | HTR1D (0.62) | HTR1DHTR1B | |
| SCHEMBL4346229 | 0.77 | HTR2C (0.72) | HTR1DHTR1BHTR2CCYP2D6HTR1A | |
| SCHEMBL8058959 | 0.76 | HTR1D (0.67) | HTR1DHTR1B | |
| SCHEMBL8643487 | 0.73 | CYP2D6 (0.45) | HTR1DHTR1BCYP2D6 | |
| SCHEMBL8413585 | 0.73 | HTR1D (0.80) | HTR1DHTR1BHTR2C | |
| SCHEMBL7480405 | 0.72 | HTR2C (0.50) | HTR1DHTR1BHTR2CCYP2D6HTR1A | |
| SCHEMBL30825703 | 0.72 | ENPP2 (0.46) | CYP2D6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| CN-101035537-A | Compositions and methods for treating ocular diseases | MERCK & CO INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | HTR1D 3404/4885HTR1B 3286/4885HTR2C 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.